Asset Details
Do you wish to reserve the book?
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue
Do you wish to request the book?
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue
2020
Overview
Clinical trials have demonstrated that preexposure prophylaxis (PrEP) protects against HIV infection; yet, even with its approval by the Food and Drug Administration (FDA) in 2012, less than 10% of eligible users in the United States are currently taking PrEP. While there are multiple factors that influence PrEP uptake and pose barriers to PrEP implementation, here we focus on PrEP’s cost in the United States, which, at the current list price of$2000 per month and with high levels of cost sharing, can leave insured users with more than $ 1000 in out-of-pocket costs every year. We discuss how patient deductibles, monthly premiums, copayments, and coinsurance vary widely and may increase the financial burden. Although drug payment-assistance programs have made PrEP more affordable to uninsured and underinsured users, lack of insurance is a barrier to PrEP accessibility. The FDA approved a generic version in 2017; however, that version has not been distributed to US consumers and may not be more affordable. As other countries begin implementing PrEP programs, the extent of PrEP’s availability as a tool in the global fight against HIV remains to be seen.
Publisher
American Public Health Association
Subject
/ Acquired immune deficiency syndrome
/ Adults
/ AIDS
/ AJPH Ending the HIV Epidemic
/ Anti-HIV Agents - administration & dosage
/ Barriers
/ Costs
/ Deductibles and Coinsurance - economics
/ Drugs
/ Health Services Accessibility - economics
/ Health Services Accessibility - statistics & numerical data
/ HIV
/ HIV Infections - prevention & control
/ HIV/AIDS
/ Human immunodeficiency virus
/ Humans
/ Insurance Coverage - economics
/ Insurance Coverage - statistics & numerical data
/ Insurance, Pharmaceutical Services - statistics & numerical data
/ Medicaid
/ Medical Assistance - statistics & numerical data
/ Medicare
/ Men
/ Parents
/ Pre-Exposure Prophylaxis - methods
/ Premiums
/ Sexually transmitted diseases
/ STD
/ Uptake
